1. Matsuoka, M., Budiawan, T., Aye, K. S., Kyaw, K., Tan, E. V., Cruz, E. D., Gelber, R., Saunderson, P., Balagon, V., & Pannikar, V. (2007). The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines. Leprosy Review, 78, 343–352.
2. Musser, J. M. (1995). Antimicrobial agent resistance in mycobacteria: molecular genetics insights. Clinical Microbiology Reviews, 8, 496–514.
3. Fajardo, T. T., Villahermosa, L. G., Cruz, E. C., Cellona, R. V., Balagon, M. V., Abalos, R. M., & Gelber, R. H. (2004). A clinical trial of pefloxacin and ofloxacin in lepromatous leprosy. Leprosy Review, 75, 389–397.
4. Yokoyama, K., Kim, H., Mukai, T., Matsuoka, M., Nakajima, C., & Suzuki, Y. (2012). Impact of amino acid substitutions in B subunit of DNA gyrase in Mycobacterium leprae on fluoroquinolone resistance. PLoS Neglected Tropical Diseases, 6, e1838.
5. Schoeffler, A. J., & Berger, J. M. (2008). DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Quarterly Reviews of Biophysics, 4, 41–101.